Trial Profile
Proxy triplet trial of ACH-3102 and sovaprevir with sofosbuvir in patients with hepatitis C
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 22 Sep 2015
Price :
$35
*
At a glance
- Drugs Odalasvir (Primary) ; Sofosbuvir; Sovaprevir
- Indications Hepatitis C
- Focus Therapeutic Use
- 17 Sep 2015 According to a company media release, Achillion Pharmaceuticals expects to initiate this trial by early 2017.
- 16 Mar 2015 New trial record
- 05 Mar 2015 SVR4 results are expected in the second half of 2015, according to an Achillion Pharmaceuticals media release